Level of miR-101a and miR-107 in Human Adipose Mesenchymal Stem Cells Committed to Insulin-producing Cells.
Rajabi H., Aslani S., Rahbarghazi R.
Laboratory Study, published in Int J Mol Cell Med (2021) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Int J Mol Cell Med (2021)
- Country
- Iran
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 34268255
- PMCID
- PMC8256832
- DOI
- 10.22088/IJMCM.BUMS.10.1.68
- Citations
- 4
Abstract (original English)
Mesenchymal stem cells have the fundamental ability to differentiate into multiple cells such as osteoblasts, neural cells, and insulin-producing cells. MicroRNAs (miRNAs) are single-strand and small non-coding RNAs involved in stem cells orientation into mature cells. There is no comprehensive data about the dynamic of distinct miRNAs during the differentiation of mesenchymal cells from adipose tissue into insulin-producing cells. In this study, we first differentiated adipose-derived mesenchymal stem cells into insulin-producing cells by a three-stepwise protocol. Differentiation capacity was confirmed by the dithizone staining method and hormone (insulin and C peptide) release analysis via electrochemiluminescence technique. In the final phase, the expression of hsa-miR-101a and hsa-miR-107 and two pancreatic genes, sex-determining region Y-box ( SOX ) 6 and neuronal differentiation 1 ( NeuroD1 ) were examined during the differentiation procedure on days 0, 7, 14, 21, and 28 after induction, by using real-time PCR assay. The level of C-peptide and insulin were also measured at the end of the experiment. Dithizone staining showed trans-differentiation of adipose-derived mesenchymal stem cells into pancreatic β cells evidenced with red-to-brown appearance compared to the control group, indicating the potency to insulin production. These features were at maximum levels 28 days
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.